		Substitute for form 1449A/PTO	Complete if Known				
IN	FORMA	ATION DISCLOSURE	Application Number	10/706,70			
ST	ATEMI	ENT BY APPLICANT P	Filing Date	Novembe	r 12, 2003		
			First Name Inventor	Paul Lehr	nann		
	(Use sev	veral sheets if necessary)	Group Art Unit				
		2 2 2004 G	Examiner Name		· _ · _		
Sheet			Attorney Docket Number	21435			
		D. ILSVPAT	ENT DOCUMENTS				
	r	U.S. Patent Document	1 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	T			
Examiner	Cite		Name of Patentee or Appl	icant of	Date of Publicatio	n of	
Initials'	No.	Kind Code Number (if known)	Cited Document	İ	Cited documen		
ļ					MM-DD-YYYY		
HAR	A22	2002/0065214	Iaina et al		05-30-2003		
	A23	2002/0115833	Burg et al		08-22-2002		
						$\neg \neg$	
ļ							
ļ			<u> </u>				
			•				
			·				
		FOREIGN P	ATENT DOCUMENTS				
		Foreign Patent Document	Date of Publication of				
Examiner	Cite	Office ³ Number Kind Cod	Name of Patentee or	Cited Document			
Initials'	No.'	(if known)	Applicant of Cited Docum	ent Mi	M-DD-YYYY		
						\dashv	
			 				
		1					
		· · · · · · · · · · · · · · · · · · ·					
						\dashv	
Examiner Signature	HM	Date Considered 8/29/	05	,			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

Tex. Amin's R: initial in reference considered, whether or not change is in communate with MPEP 609. Draw the intrough extrion it not in communication to applicant.

Unique citation designation number. See strached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST...). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under YIPO Standard ST... 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.

pe Kobinsie

		-		1449A/PTO	Complete if Known			
	INFORMA	ATION	DIS	CLOSURP E	Application Number	10/706,701		
	STATEM	ENT B	Y Al	PPLICANT \	Filing Date	November 12, 2003		
			- 1	/	First Name Inventor	Paul Lehmann		
	(Use sev	veral shee	ts if ¢	eces##R) 2 9 2004	Group Art Unit			
			,		Examiner Name			
Sheet	2	Of	2	To made	Attorney Docket Number	21435		
				ייאים מינים				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials' Cite Initi			NUN PATENT LITERATURE DOCUMENTS	
C26 THOMAS CHRISTIAN ET AL, Clinical Chemistry, Amer. Assoc. for Clin. Chem. Vol 48(7) (2002) pgs. 106-1076 C27 PEETERS H R M ET AL, Rheumatology International, Vol 18, (1999) pgs. 201-206 C28 DE VALK B, ET AL, Archives of Internal Medicine, Vol 159(14) (1999) pgs. 1542-1548			of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-	T ²
Assoc. for Clin. Chem. Vol 48(7) (2002) pgs. 106-1076 C27 PEETERS H R M ET AL, Rheumatology International, Vol 18, (1999) pgs. 201-206 C28 DE VALK B, ET AL, Archives of Internal Medicine, Vol 159(14) (1999) pgs. 1542-1548	A	C26		
(1999) pgs. 201-206 C28 DE VALK B, ET AL, Archives of Internal Medicine, Vol 159(14) (1999) pgs. 1542-1548	THE_		Assoc. for Clin. Chem. Vol 48(7) (2002) pgs. 106-1076	
(1999) pgs. 201-206 C28 DE VALK B, ET AL, Archives of Internal Medicine, Vol 159(14) (1999) pgs. 1542-1548		C27	PEETERS H R M ET AL, Rheumatology International, Vol 18,	,
C28 DE VALK B, ET AL, Archives of Internal Medicine, Vol 159(14) (1999) pgs. 1542-1548	j			
159(14) (1999) pgs. 1542-1548 159(14) (1999) pgs. 1542-1548 Examiner DATE DATE	-+	C28	DE VALK B. ET AL. Archives of Internal Medicine, Vol	
		1		

		+		
		-		_
		 		
	···-·	 		
		 		_
		 		
		 		
		-		
		+		
	Examiner	1	P 17 Sea DATE OF 0/2 CT	
Signature CUNSIDERED 1 with 15 of the second signature	Signature	QW.	CONSIDERED 8/27/03	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *Applicant is to place a check mark here if English language Translation or abstract is attached.

141704

Г			Substitute for	form 1449A/PTO		Comp	lete if Kno	wn	
1	INI	ORMA	TION I	DISCLOSUE	₹E	Application Number	10/706,	701	
1P	E ST.	ATEMI	ENT BY	APPLICAN	iT [Filing Date	Novemb	er 12, 2003	
1	` &					First Name Inventor	Lehman	n	
Ι.	()	(Use sev	eral sheets	if necessary)		Group Art Unit			
۱ ۱						Examiner Name			
S					,	Attorney Docket Number	21435	US	
\vdash	المحكاد				U.S. PAT	ENT DOCUMENTS			
4C	تعنظنظن	[U.S	. Patent Docu	ment				
	xaminer	Cite			Kind Code	Name of Patentee or Ap		Date of Publication	
I	nitials'	No.'	Number		(if known)	Cited Documer	Cited documer MM-DD-YY		
\vdash	110	421	C 440	022	T .	Tohmonn et al	08-27-2002		
Ľ	HIX_	A21	6,440,	932	<u> </u>	Lehmann, et al.		08-27-2002	
L								 	
L									
\vdash			-						
\vdash			-		 				
\vdash					 	 			
_					 				
L					ļ				
	•								
\vdash				···········			**-		
-				· · · · · · · · · · · · · · · · · ·	 				
\vdash		l	L	FO	DEICN P	ATENT DOCUMENTS		L.,	
\vdash		· · · · · ·	Foreign	Patent Docum		WIENI DOCUMENIS		Date of	Т
F	xaminer	Cite				Name of Patente	Publication of	•	
	nitials'	No.'	Office ³	Number ⁴	Kind Cod	e Applicant of Cited D		Cited	
1					(11 22 20 41.)	Docui MM-		Document	
								MM-DD-	
\vdash	7/0/	DOZ	11/0 0	2/25592	1 42	E Heffmann La Backs AC		03-27-2003	├
μ'	1-10K-	B27	WO 0	3/25583	A2	F.Hoffmann-La Roche AG		03-27-2003	
L									<u> </u>
L									
T		-							
-								1	
\vdash				 -				 	-
\vdash								 	-
				· .		<u>, </u>		ļ <u>.</u>	<u> </u>
E	xaminer		Date Co	nsidered	81	29/0-			

Signature

Sylvan IV

SEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMMENT: finital in reference considered, whether to that of utation is an observable of the reference considered, whether to that instance and in the comment of the reference considered. The reference of the results of the reference of the results of the res

Hope Robonia

Compl	Complete if Known			
Application Number	10/706,701			
Filing Date	November 12, 2003			
First Name Inventor	Lehmann			
Group Art Unit				
Examiner Name				
Attorney Docket Number	21435 US			
	Application Number Filing Date First Name Inventor Group Art Unit Examiner Name			

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Cite No.1 Examiner Initials' DEVITA MV, et al., Clin Nephrol, 60(5):335-40 (2003) C25 Signature CONSIDERED 29/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached. DATE

TE E		Substitute for form	1449A/PTO		Complete if Known				
		ATION DIS			Application Number				
ST	STATEMENT BY APPLICANT				Filing Date		per 12, 2003		
AAPTA STA	(lise sev	eral sheets if n	ecessary)		First Name Inventor	Lehman	n, et al.		
Sheet 1		of 3		·	Attorney Docket Number	21435 L	JS		
					ENT DOCUMENTS				
		U.S. P	atent Docum	nent	Name of Patentee or App	licent of	Date of Publication of		
Examiner Initials'	Cite No.'			Kind Code	Cited Document	iicaii 01	Cited document		
		Number		(if known)			MM-DD-YYYY		
	A1	4,179,33	7		Davis et al.		12/18/1979		
	A2	4,745,099	9		Akamatsu et al.		05/17/1988		
	A3	5,272,07	<u> </u>		Chappel		12/21/1993		
	A4	5,324,650	0		Obzansky et al.		06/28/1994		
	A5	5,359,030	0		Ekwuribe		10/25/1994		
	A 6	5,376,632	2		Konings et al.		12/27/1994		
	A7	5,541,15	8		Vance et al.		07/30/1996		
	A8 5,641,670 A9 5,672,662				Treco et al.	06/24/1997			
					Harris et al.	09/30/1997			
	A10	5,681,81	1		Ekwuribe	10/28/1997 03/31/1998			
	A11	5,733,740	5		Treco et al.				
	A12	5,733,76	1		Treco et al.	<u> </u>			
	A13	5,981,214	4		Skoultchi	11/09/1999			
	A14	5,994,12	7		Selden et al.	11/30/1999 12/25/2001 01/22/2002			
	A15	6,333,30	5		Lehmann et al.				
	A16	6,340,742	2		Burg et al.				
	A17	6,372,713	5		Kaltwasser et al.	04/16/2002			
	A18	6,528,313	3		Le Mouellic et al.	03/04/2003			
	A19	6,583,272	2		Bailon	06/24/2003			
1	A20	US 2002/0160956 A1		Al	Lehmann et al.	10/2002			
			FOR	EIGN P	ATENT DOCUMENTS				
	T	Foreign Patent Document					Date of T ⁶		
Examiner Initials'	Cite No.	Office ³	Number ⁴	Kind	Name of Patentee of Applicant of Cited Doc		Publication of Cited Document		
minais	110.			Code ⁵			MM-DD-YYYY		
. 1				(if known)					
die	B1 WO 93/09222		Transkaryotic Therapie	es, Inc.	05/13/1993				
1	B2 WO 94/12650 B3 WO 95/31560		Transkaryotic Therapie		06/09/1994				
			Transkaryotic Therapie	_	11/23/1995				
	B4 WO 90/11354				Institut Pasteur		10/04/1990		
	B5	WO 91/	06667		Cell Genesys Inc.		05/16/1991		
	B6	WO 91/			Applied Research Syst		07/11/1991		
<u> </u>	B7	WO 01/			F.Hoffmann-La Roche		01/11/2001		
W	B8	EP 1064	1951		F.Hoffmann-La Roche DATE	AG	01/03/2001		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Signature

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents, ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/706,701 Filing Date November 12, 2003 First Name Inventor Lehmann, et al.

(Use several sheets if necessary) of 3 Sheet

21435 US Attorney Docket Number

FORFICN PATENT DOCUMENTS

Examiner	Cite	Foreign Patent Document		nent	Name of Patentee or	Date of Publication of	Té
Initials'	No.'	Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	
JAX	B9	EP 539	167		Ortho Pharmaceutical Corp.	04/28/1993	
	B10	EP 605	963		Ortho Pharmaceutical Corp.	07/13/1994	
	B11	WO 93/	25212		Amgen Inc.	12/23/1993	
B12 WO 94/20069			Amgen Inc.	09/15/1994			
	B13				Enzon, Inc.	05/04/1995	
	B14				Sterling Winthrop Inc.	03/02/1994	
	B15 WO 92/16555		Enzon, Inc.	10/01/1992			
B17 WO 97/04796 B18 WO 98/32466		/28024		Enzon, Inc.	12/08/1994 02/13/1997		
		WO 97/04796				Protein Delivery, Inc.	
		Polymasc Pharmaceutical PLC	07/30/1998				
		Boehringer Mannheim GmbH	01/31/1991				
	B20	WO 01/87329			F.Hoffmann-La Roche AG	11/22/2001	
	B21	EP 640	519		Amgen Inc.	03/01/1995	
	B22	EP 0411678			Genetics Institute Inc.	02/06/1991	
	B23	EP 020	5564		Genetics Institute Inc.	12/30/1986	
	B24	EP 028	5439		Ortho Pharmaceutical Corp.	10/12/1988	
	B25	WO 97/	09996		Boehringer Mannheim GmbH	03/20/1997	
4	B26	WO 98/	41226		Boehringer Mannheim GmbH	09/24/1998	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²						
AK	C1	P. Lehmann, M. Volkmann, J. Lotz, A. Baldauf, R. Roeddiger, poster presented at the AACC/CSCC, Annual Meeting, July 29 - August 2, 2001, Chicago Illinois							
	C2	March J., Advanced Organic Chemistry, McGraw-Hill, 1977, pgs. 375-376							
	C3	Grasetti, D. R. & Murray, J. F., J. Appl. Biochem. Biotechnol. 119, pgs. 41-49, 1967							
	C4	Morpurgo M. et al., J. Bioconj. Chem. (1996) Vol. 7, pgs. 363-368							
	C5	Hermanson, G. T. Bioconjugate Techniques Academic Press, San Diego (1996) pgs. 147-148							
	C6	Annable, et al. Bull. Wld. Hlth. Org. (1972) Vol. 47 pgs. 99-112							
	C7	Abstract corresponding to WO 90/11354 (B4)							
V	C8	Abstract corresponding to DE 3924705 (B19)							
Examiner Signature		Hope Pibinger DATE CONSIDERED 8/29/05	.]						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

Complete if Known ETHE TRADE Substitute for form 1449A/PTO 10/706,701 INFORMATION DISCLOSURE **Application Number** STATEMENT BY APPLICANT November 12, 2003 Filing Date First Name Inventor Lehmann, et al. (Use several sheets if necessary) Sheet of 3 Attorney Docket Number 21435 US

Initials' No. item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s)		NON PATENT LITERATURE DOCUMENTS
publisher, etcy mile or country where published	 	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

.)

Initials'	No.1	item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
THK.	, C9	Grützmacher P., et al., Clinical Nephrology, vol. 38, pp 92-97, 1992	
HAR	C10	Wick, M.; Pinggera, W.; Lehmann, P., Eisenstoffwechsel Diagnostik und Therapie der Anämien, 3 rd Edition, Springer, Wien, NY, pp 5-14, 38-55, 65-80, 94-98, Sept. 1996	
	C11	Sunder-Plassmann G., et al., <i>Journal of the American Society of Nephrology</i> , 5, (3), pp 478 (1994).	
	C12	Gasche C., et al., Dig. Dis. Sci., 39, (9) pp 1930-4 (1994).	
	C13	Sunder-Plassmann G., et al., <i>Nephrology Dialysis Transplantation</i> , 10, (11), pp 2070-2076 (1995).	
	C14	Mercuriali F. et al., Erythropoiesis: New Dimensions in the Treatment of Anaemia, 6/3, pp 67-76, (1995).	
	C15	Sunder-Plassmann G., et al., Nephrology Dialysis Transplantation, 11, (9), pp 1797-1802, (1996).	
	C16	Taylor J. E., et al., Nephrology Dialysis Transplantation, 11, (6), pp 1079-1083, (1996).	
	C17	Breymann, et al., Eur. J. Clin. Invest., pp 123-30.	
	C18	Goodnough, et al., Haematology, 1(2), pp 163-166.	
	C19	MacDougall (1994) Monitoring of Iron Status & Iron Supplementation in Patients Treated with Erythropoietin. Current Opinion in Nephrology & Hypertension 3(6) pgs. 620-625	
	C20	Taylor et al. (1996) Regular low-dose Intravenous Iron Therapy Improves Response to Erythropoietin in Haemodialysis Patients. <i>Nephrology, Dialysis, & Transplantation</i> 11(6) pgs. 1079-1083	
	C21	Means, Jr. (1995) Erythropoietin in the Treatment of Anemia in Chronic Infectious, Inflammatory, & Malignant Diseases. Current Opinion in Hematology 2(3) pgs. 210-213	
	C22	Adamson (1996) Erythropoietin, Iron Metabolism, & Red Blood Cell Production. Seminars In Hematology 33(2) pgs. 5-9	
	C23	Mercuriali & Inghilleri (1995) Iron Administration to Optimize the Effect of r-HuEPO in the Surgical Setting. Erythropoiesis: New Dimensions in the Treatment of Anemia 6(3) pgs. 67-76	
	C24	Pincus et al. (August, 1990) Multicultural Study of Recombinant Human Erythropoietin in Correction of Anemia in Rheumatoid Arthritis. <i>The American Journal of Medicine</i> 89(2) pgs. 161-168.	

		·								
Examiner		Ī	ا کا	(20		DATE	C	/2 0	120	_
Signature	L Q	HDe	7-0/	22/20	7	CONSIDERED	8	127	<u>/ v) </u>	
							7			$\overline{}$

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Inclu copy of this form with next communication to applicant.

*Unique citation designation number. *Applicant is to place a check mark here if English language Translation or abstract is attached.